EGFR and lung cancer: Current understanding surrounding the depth and duration of response to oncogene-targeted inhibitors suggests that the extent to which chemokine induction occurs with oncogene-specific therapies associates with the degree of response, as EGFR mutant lung cancer patients exhibiting greater interferon γ transcriptional responses to TKIs presented with longer progression-free survival (17).